A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center
Cancer Reports · 2024
DOI: 10.1002/cnr2.70046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Franciscus A Diepstraten und 12 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands. Hauptthemen laut MEDLINE: Ototoxicity, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Ototoxicity is an adverse effect of childhood cancer treatment with a negative impact on speech‐language development and quality of life. This study aimed to retrospectively assess ototoxicity monitoring in a national cohort of pediatric patients with solid tumors, examining the frequency and determinants associated with hearing loss (HL).
Methods
This retrospective cohort study included 305 patients treated between 2015 and 2020 at the Princess Máxima Center. Patients receiving platinum agents, head and neck radiotherapy, and/or ear‐nose‐throat surgery were analyzed. Electronic patient files provided demographic, clinical, and audiological data. HL was defined as Muenster ≥ 2b or SIOP ≥ 2 grade. Associations between clinical characteristics and HL occurrence were analyzed using logistic regression analysis.
Results
Audiological monitoring was performed at baseline (62.6%), during treatment (79.0%), and at the end of treatment (82.1%). Post treatment, 51.2% and 36.5% experienced Muenster and SIOP‐defined HL, respectively. Multivariable analyses revealed that age at diagnosis (OR 0.9, 95% CI 0.9–1.0), total cumulative dose cisplatin per 100 mg/m 2 (OR 1.6, 95% CI 1.4–2.0), and vincristine treatment (OR 3.3, 95% CI 1.4–7.8) remained significantly associated with Muenster grade ≥ 2b HL. Age at diagnosis in years (OR 0.9, 95% CI 0.8–1.0), total cumulative dose cisplatin per 100 mg/m 2 (OR 1.5, 95% CI 1.2–1.8), and male sex (OR 2.7, 95% CI 1.4–5.3) were associated with SIOP ≥ 2 HL.
Conclusion
This study shows that more than half of the children treated with ototoxic cancer therapies develop HL by the end of treatment. Therefore, audiological monitoring during and after treatment is essential. Improved insight into clinical determinants aids in identifying patients at high risk for HL, who may benefit from prevention strategies that are currently being implemented.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
- Department of Audiology, University Medical Center Utrecht, Utrecht, Netherlands.
- Department of Otorhinolaryngology-Head and Neck Surgery, University Medical Center Utrecht, Utrecht, Netherlands.
- UMC Brain Center, University Medical Center Utrecht, Utrecht, Netherlands.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
- University Medical Center Utrecht-Wilhelmina Children's Hospital, Utrecht, Netherlands.
ORCID-Profile: Franciscus A Diepstraten, Martine van Grotel, Harm van Tinteren
Zitieren
APA
Diepstraten, F. A., Bertram, O. M. M., Helleman, H. W., Boerboom, R. A., van Grotel, M., Zsíros, J., Tytgat, G. A. M., van Tinteren, H., Stokroos, R. J., Janssens, G. O., Hoetink, A. E., van den Heuvel-Eibrink, M. M., & Meijer, A. J. M. (2024). A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center. Cancer Reports. https://doi.org/10.1002/cnr2.70046
Vancouver
Diepstraten FA, Bertram OMM, Helleman HW, Boerboom RA, van Grotel M, Zsíros J, et al. A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center. Cancer Reports. 2024. doi:10.1002/cnr2.70046
BibTeX
@article{Diepstraten2024,
author = {Diepstraten, Franciscus A and Bertram, Odette M M and Helleman, Hiske W and Boerboom, Ralf A and van Grotel, Martine and Zsíros, József and Tytgat, Godelieve A M and van Tinteren, Harm and Stokroos, Robert J and Janssens, Geert O and Hoetink, Alex E and van den Heuvel-Eibrink, Marry M and Meijer, Annelot J M},
title = {A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.70046}
}
EUVIMED